BioXcel Therapeutics ( NASDAQ: BTAI ) has commenced an underwritten public offering of shares of its common stock, par value $0.001/share , and accompanying warrants to purchase shares, and, in lieu thereof to certain investors that so choose, pre-funded warrants to purchase shares of Common.
Back to Health Page
